指南与共识血栓与止血

儿童COVID-19相关疾病住院抗凝血栓预防共识建议

Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness.
指南 / 共识 · J Thromb Haemost · 2020-01-01

该共识基于20名儿科血液与重症专家的调查(应答率90%)及文献综述,建议对D-二聚体显著升高或存在医院相关VTE临床危险因素的COVID-19相关疾病住院儿童,采用低剂量低分子肝素皮下每日两次抗凝预防,并联合机械预防;临床不稳定或严重肾损害者建议持续静脉输注普通肝素。未来需多中心试验明确VTE风险及预防策略的安全性与有效性。

要点

  • D-二聚体显著升高或存在医院相关VTE危险因素的住院患儿建议低剂量低分子肝素每日两次皮下注射。
  • 低分子肝素预防需排除禁忌证,并尽可能联合序贯加压装置机械预防。
  • 临床不稳定或严重肾损害患儿建议持续静脉输注普通肝素进行抗凝预防。

核心结论

  • 基于专家共识,建议对具有明显D-二聚体升高或叠加临床危险因素的COVID-19相关疾病住院儿童进行抗凝血栓预防。
  • 临床不稳定或严重肾损害患儿建议使用普通肝素持续静脉输注。
  • 共识强调需通过多中心合作试验进一步明确儿童VTE风险及预防策略的安全性和有效性。

研究设计与样本

  • 制定机构与方法:由儿科/新生儿止血与血栓形成小组委员会领导层确定的20名儿科血液学家和儿科重症监护医师参与调查,并进行了儿童COVID-19文献的综合回顾。

主要发现

  • 调查应答率为90%。
  • 基于专家意见共识,建议对D-二聚体显著升高或存在叠加临床危险因素的COVID-19相关疾病住院儿童(包括MIS-C)使用低剂量低分子肝素皮下每日两次抗凝预防。
  • 对于临床不稳定或严重肾损害的儿童,建议使用普通肝素持续静脉输注。
  • 未来研究重点包括明确儿童COVID-19的VTE风险和危险因素,以及通过多中心试验评估抗凝预防策略的安全性和有效性。

关键数值与推荐

  • 推荐条款:对D-二聚体显著升高或存在叠加临床危险因素的COVID-19相关疾病住院儿童(包括MIS-C),在无禁忌证且尽可能联合序贯加压装置机械预防的情况下,建议低剂量低分子肝素皮下每日两次。
  • 推荐条款:对临床不稳定或严重肾损害的儿童,建议普通肝素持续静脉输注。

临床怎么用

  • 临床可依据患儿D-二聚体水平及医院相关VTE临床危险因素,决定是否启动低剂量低分子肝素抗凝预防。
  • 启动药物预防前需评估禁忌证,并尽可能联合序贯加压装置进行机械预防。
  • 对临床不稳定或严重肾损害患儿,选择普通肝素持续静脉输注而非低分子肝素。

局限性

  • 目前缺乏高质量证据指导临床实践,共识基于专家意见和文献回顾。
  • 调查仅纳入20名专家,应答率90%,共识意见需随高质量证据出现而更新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational studies indicate that children hospitalized with COVID-19-related illness, like adults, are at increased risk for venous thromboembolism (VTE). A multicenter phase 2 clinical trial of anticoagulant thromboprophylaxis in children hospitalized with COVID-19-related illness has recently been initiated in the United States. To date, there remains a paucity of high-quality evidence to inform clinical practice world-wide. Therefore, the objective of this scientific statement is to provide consensus-based recommendations on the use of anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illnesses, and to identify priorities for future research. METHODS: We surveyed 20 pediatric hematologists and pediatric critical care physicians from several continents who were identified by Pediatric/Neonatal Hemostasis and Thrombosis Subcommittee leadership as having experience and expertise in the use of anticoagulant thromboprophylaxis and/or the management of COVID-19-related illness in children. A comprehensive review of the literature on COVID-19 in children was also performed. RESULTS: Response rate was 90%. Based on consensus of expert opinions, we suggest the administration of low-dose low molecular weight heparin subcutaneously twice-daily as anticoagulant thromboprophylaxis (in the absence of contraindications, and in combination with mechanical thromboprophylaxis with sequential compression devices, where feasible) in children hospitalized for COVID-19-related illness (including the multisystem inflammatory syndrome in children [MIS-C]) who have markedly elevated D-dimer levels or superimposed clinical risk factors for hospitalassociated VTE. For children who are clinically unstable or have severe renal impairment, we suggest the use of unfractionated heparin by continuous intravenous infusion as anticoagulant thromboprophylaxis. In addition, continued efforts to characterize VTE risk and risk factors in children with COVID-19, as well as to evaluate the safety and efficacy of anticoagulant thromboprophylaxis strategies in children hospitalized with COVID-19-related illness (including MIS-C) via cooperative multicenter trials, were identified among several key priorities for future research. CONCLUSION: These consensus-based recommendations on the use of anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illnesses and priorities for future research will be updated as high-quality evidence emerges.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Goldenberg NA, Sochet A, Albisetti M, et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost. 2020. PMID: 33174388. doi:10.1111/jth.15073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。